March 2005
Worldwide Biotech;Mar2005, Vol. 17 Issue 3, p7
Trade Publication
Reports on the move of the British Medicines and Healthcare products Regulatory Agency to approve a human trial of the drug Melanotan developed by EpiTan Ltd. in March 2005. Details of the clinical trial; Importance of Melanotan in preventing and treating skin diseases associated with ultra-violet radiation; Ability of the drug to induce melanin production.


Related Articles

  • Alefacept. Şahin, Mustafa Turhan // Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry;Aug2007, Vol. 6 Issue 3, p211 

    Alefacept is a fully human fusion protein, being the first biologic agent approved for the treatment of chronic, moderate to severe plaque-type psoriasis. Its dual mechanism of action involves inhibition of T-cell activation and selective reduction of memory T cells. It has a slow onset of...

  • Look Beyond Financial Conflicts of Interest in Evaluating Industry–Academia Collaborations in Burden-of-Illness and Outcomes Research Studies in Dermatology. Prendergast, Mary M.; Abramovits, William; Boguniewicz, Mark; Lebwohl, Mark; Tokar, Michael; Tong, Kuo B. // Journal of Investigative Dermatology;Sep2004, Vol. 123 Issue 3, p452 

    Financial relationships exist among industry, scientific investigators, and academic medical centers. These relationships can foster research in the basic sciences, clinical trials, health economics evaluations, and other outcomes assessment studies. To govern the conduct of burden-of-illness...

  • Application of Pharmacokinetic-Pharmacodynamic Modeling and the Justification of a Novel Fusidic Acid Dosing Regimen: Raising Lazarus From the Dead. Tsuji, Brian T.; Okusanya, Olanrewaju O.; Bulitta, Jurgen B.; Forrest, Alan; Bhavnani, Sujata M.; Fernandez, Prabha B.; Ambrose, Paul G. // Clinical Infectious Diseases;2011, Vol. 52 Issue Suppl 7, pS513 

    Perhaps the most crucial step in the clinical development of an antimicrobial agent is the selection of a dosing regimen. Such decisions impact not only the success of a program but also the well being of individual patients, the emergence of resistance, and society as a whole. For fusidic acid,...

  • New Rules for Clinical Research. Wechsler, Jill // Applied Clinical Trials;May2001, Vol. 10 Issue 5, p24 

    Reports on federal agencies' overhauling of human subject research policies. Changing research infrastructure; Expansion of the oversight of the United States Food and Drug Administration.

  • Two accreditors coalesce on research subject protection.  // Getting Paid in Behavioral Healthcare;Mar2003, Vol. 8 Issue 3, p6 

    Reports on the partnership formed between the National Committee for Quality Assurance and the Joint Commission on Accreditation of Healthcare Organizations for the purpose of establishing an accreditation program for efforts to protect human subjects in research. Focus of the Partnership for...

  • Using clinical trials and technology to help patients. Baldwin, Fred D. // Ophthalmology Times;04/15/99, Vol. 24 Issue 8, p42 

    Provides information on the participation of patients in clinical trials and technology. Stand of physicians in clinical trials; Clinical situations which a clinical trial becomes an appropriate treatment option; Why doctors need to be aware of trials as options; How clinical trials work.

  • Clinical Research and the Physician-Patient Relationship. Chen, Donna T.; Miller, Franklin G.; Rosenstein, Donald L. // Annals of Internal Medicine;4/15/2003, Vol. 138 Issue 8, p669 

    All practicing physicians should be prepared to respond to requests from patients for advice about participating in clinical trials research. Even physicians who choose not to conduct clinical trials but rather devote their practice to clinical care may have patients who consider volunteering...

  • EPT'S IMPLANT TRIAL EXCEEDS EXPECTATION.  // Worldwide Biotech;Apr2004, Vol. 16 Issue 4, p4 

    Reports on the efficacy in the implant dose escalation trial by EpiTan Limited in Melbourne, Australia, which commenced in November 2003. Objective of the trial; Expectations of EpiTan on the conclusion of the implant trial; Background of EpiTan.

  • Clinical Trials in CEE: Harnessing the Potential. Motteram, Peter A.S.; Richardson, Andy // Applied Clinical Trials;Sep2004, Vol. 13 Issue 9, p50 

    Provides an overview on the field of clinical trials in Central and Eastern Europe (CEE). Primary factor for considering CEE sites; Nonprotocol issues for CEE trials; Regulations governing clinical trials; Provisions under the EU Clinical trials Directive.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics